In Nov. 2022, the U.S. nonprofit Multidisciplinary Affiliation for Psychedelic scientific studies (MAPS) declared that it had finished a 2nd stage-three trial on MDMA like a treatment method for PTSD—a move widely https://robertfden393172.blogitright.com/profile